Cargando…

Validation of the Korean version of the European Organization for Research and Treatment of Cancer brain cancer module (EORTC QLQ-BN20) in patients with brain tumors

BACKGROUND: The European Organization for Research and Treatment of Cancer Quality of Life Brain Cancer Module has been translated into Korean, but to date, its reliability and validity have been evaluated in a pilot study alone. The European Organization for Research and Treatment of Cancer Quality...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Yong Soon, Kim, Jeong Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3766694/
https://www.ncbi.nlm.nih.gov/pubmed/23981813
http://dx.doi.org/10.1186/1477-7525-11-145
_version_ 1782477313037828096
author Shin, Yong Soon
Kim, Jeong Hoon
author_facet Shin, Yong Soon
Kim, Jeong Hoon
author_sort Shin, Yong Soon
collection PubMed
description BACKGROUND: The European Organization for Research and Treatment of Cancer Quality of Life Brain Cancer Module has been translated into Korean, but to date, its reliability and validity have been evaluated in a pilot study alone. The European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire is, overall, a valid instrument to assess the health-related quality of life in Korean cancer patients, although its reliability and validity have not yet been evaluated in patients with brain tumors. This study aimed at evaluating the psychometric properties of these instruments in patients with brain tumors. FINDINGS: The 2 instruments were used for 307 Korean patients with brain tumors. Multi-trait scaling confirmed the scale structure of the instruments with good item convergent and discriminant validity. The reliability was acceptable for all scales except for cognitive functioning and nausea and vomiting. The instruments could be used to distinguish between clinically distinct groups of patients. CONCLUSIONS: The study findings indicate that the instruments are valid and suitable for the assessment of the health-related quality of life in patients with brain tumors as well as in those with primary brain cancer.
format Online
Article
Text
id pubmed-3766694
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-37666942013-09-09 Validation of the Korean version of the European Organization for Research and Treatment of Cancer brain cancer module (EORTC QLQ-BN20) in patients with brain tumors Shin, Yong Soon Kim, Jeong Hoon Health Qual Life Outcomes Short Report BACKGROUND: The European Organization for Research and Treatment of Cancer Quality of Life Brain Cancer Module has been translated into Korean, but to date, its reliability and validity have been evaluated in a pilot study alone. The European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire is, overall, a valid instrument to assess the health-related quality of life in Korean cancer patients, although its reliability and validity have not yet been evaluated in patients with brain tumors. This study aimed at evaluating the psychometric properties of these instruments in patients with brain tumors. FINDINGS: The 2 instruments were used for 307 Korean patients with brain tumors. Multi-trait scaling confirmed the scale structure of the instruments with good item convergent and discriminant validity. The reliability was acceptable for all scales except for cognitive functioning and nausea and vomiting. The instruments could be used to distinguish between clinically distinct groups of patients. CONCLUSIONS: The study findings indicate that the instruments are valid and suitable for the assessment of the health-related quality of life in patients with brain tumors as well as in those with primary brain cancer. BioMed Central 2013-08-27 /pmc/articles/PMC3766694/ /pubmed/23981813 http://dx.doi.org/10.1186/1477-7525-11-145 Text en Copyright © 2013 Shin and Kim; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Report
Shin, Yong Soon
Kim, Jeong Hoon
Validation of the Korean version of the European Organization for Research and Treatment of Cancer brain cancer module (EORTC QLQ-BN20) in patients with brain tumors
title Validation of the Korean version of the European Organization for Research and Treatment of Cancer brain cancer module (EORTC QLQ-BN20) in patients with brain tumors
title_full Validation of the Korean version of the European Organization for Research and Treatment of Cancer brain cancer module (EORTC QLQ-BN20) in patients with brain tumors
title_fullStr Validation of the Korean version of the European Organization for Research and Treatment of Cancer brain cancer module (EORTC QLQ-BN20) in patients with brain tumors
title_full_unstemmed Validation of the Korean version of the European Organization for Research and Treatment of Cancer brain cancer module (EORTC QLQ-BN20) in patients with brain tumors
title_short Validation of the Korean version of the European Organization for Research and Treatment of Cancer brain cancer module (EORTC QLQ-BN20) in patients with brain tumors
title_sort validation of the korean version of the european organization for research and treatment of cancer brain cancer module (eortc qlq-bn20) in patients with brain tumors
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3766694/
https://www.ncbi.nlm.nih.gov/pubmed/23981813
http://dx.doi.org/10.1186/1477-7525-11-145
work_keys_str_mv AT shinyongsoon validationofthekoreanversionoftheeuropeanorganizationforresearchandtreatmentofcancerbraincancermoduleeortcqlqbn20inpatientswithbraintumors
AT kimjeonghoon validationofthekoreanversionoftheeuropeanorganizationforresearchandtreatmentofcancerbraincancermoduleeortcqlqbn20inpatientswithbraintumors